Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains
Primary Purpose
Clostridium Difficile Infection
Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Comparison between GenePOC PCR and Reference Method
Sponsored by
About this trial
This is an interventional diagnostic trial for Clostridium Difficile Infection
Eligibility Criteria
Inclusion Criteria:
- Unformed Stool specimens from patients suspected of having CDI for whom diagnostic tests are indicated and ordered;
- At least 1.25mL of unformed stool specimen (defined as specimen assuming the shape of its container);
- Only one (1) specimen per patient will be included in the study;
- Materials use within their expiration date;
- Transport, storage times, and conditions (e.g. room temperature and/or refrigerated) within requested indications.
Exclusion Criteria:
- Specimens from patients for whom CDI diagnostic tests have not been ordered;
- Transport and storage times and conditions that exceed these Study Protocol requirements;
- Formed or hard stool specimens or rectal swabs.
Sites / Locations
- Wishard Health Services
- John Hopkins University School of Medicine
- Detroit Medical Center University Laboratories
- Tricore Laboratory University of New Mexico
- Medical College of Wisconsin
- Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex
- McGill University Health Centre
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Accuracy Testing
Arm Description
Comparison between GenePOC PCR and Reference Method
Outcomes
Primary Outcome Measures
Performance Characteristics : Clinical Sensitivity (True Positive Rate) and Clinical Specificity (True Negative Rate) in Comparison to the Reference Method
To establish the performance characteristics of the GenePOC CDiff System for its use in determining the presence of CDiff in liquid/unformed stool specimen obtained from patients suspected of having C. difficile infection (CDI).
Sensitivity will be established as the proportion of positives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method.
Specificity will be established as the proportion of negatives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method.
Secondary Outcome Measures
Positive and Negative Predictive Values (PPV and NPV)
To estimate the Positive and Negative Predictive Values (PPV and NPV) of the GenePOC CDiff System.
PPV is the percentage of true positives out of all positive results (true positive/true positive + false positive).
NPV is the percentage of true negatives out of all negative results (true negative/true negative +false negative.).
Unresolved Sample Results
To estimate the rate of unresolved results for the GenePOC CDiff System due to Sample Processing control failure (unresolved sample results).
Indeterminate Sample Results
To estimate the rate of indeterminate results for the GenePOC CDiff Test due to an Instrument failure (indeterminate sample results).
Full Information
NCT ID
NCT02968758
First Posted
November 15, 2016
Last Updated
April 29, 2021
Sponsor
Meridian Bioscience, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT02968758
Brief Title
Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains
Official Title
Prospective Multi-Center Study for Clinical Validation of the Molecular-Based GenePOC CDiff System for the Detection of Toxin B Gene From Toxigenic Clostridium Difficile Strains in Unformed (Soft or Liquid) Human Stool Specimens
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
February 6, 2017 (Actual)
Primary Completion Date
August 2, 2017 (Actual)
Study Completion Date
August 10, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Meridian Bioscience, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary purpose of this clinical investigation is to verify the performance of the GenePOC CDiff test on the GenePOC instrument. This will be achieved by comparing the GenePOC CDiff test to the Toxigenic Culture (TC) and cell cytotoxicity neutralisation assay (CCNA), a conventional method considered as gold standard for detection of toxigenic Clostridium difficile in stool specimens.
Detailed Description
The GenePOC CDiff test performed on the GenePOC™ instrument is a qualitative in vitro diagnostic (IVD) test that utilizes automated sample preparation and real-time polymerase chain reaction (rtPCR) to detect the toxin B (tcdB) gene of toxigenic Clostridium difficile (C. difficile) in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI).
The GenePOC CDiff system comprises the GenePOC instrument and the GenePOC CDiff test, which consists of:
Transfer Loop (TL)
CDiff disposable microfluidic cartridges (PIE) (described in this document as PIEs because of the shape of the cartridge)
CDiff Sample Buffer Tube (SBT)
Disposable Transfer Tool (DTT).
The GenePOC Instrument is fully automated and integrates sample lysis, dilution, amplification and detection of the target sequence in complex samples using real-time Polymerase chain reaction (rtPCR). User intervention is only required for discharging the patient sample into the SBT (sample Buffer Tube), transferring the sample into the PIE and for loading/unloading the PIEs into the instrument. The GenePOC instrument consists of a rotor to spin the PIEs, temperature control, fluorescence detection, a tactile user-friendly interface, two barcode readers, and integrated firmware and software to deliver results to the user. The PIE is a closed system that prevents the risk of contamination.
An unformed (soft or liquid) stool specimen is collected using standard stool collection device. Using a disposable 5µL inoculating loop (transfer loop) dipped into the homogenized stool specimen, stool material is transferred into SBT and vortexed. Sample is then transferred to the GenePOC CDiff PIE. The GenePOC CDiff PIE is then automatically processed by the GenePOC Instrument. On completion of a run, the user removes the processed PIEs from the instrument and discards them according to local biological waste management procedures.
One GenePOC instrument per site will be allocated. The purpose of the clinical investigation is to enroll sufficient specimens from up to 7 Clinical Centers to obtain a total of 150 specimens positive for CDiff based on the Reference Method final result.
Subject Informed consent is not required for this clinical trial as the testing will be performed on excess de-identified specimens only.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clostridium Difficile Infection
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2461 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Accuracy Testing
Arm Type
Experimental
Arm Description
Comparison between GenePOC PCR and Reference Method
Intervention Type
Device
Intervention Name(s)
Comparison between GenePOC PCR and Reference Method
Intervention Description
Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
Primary Outcome Measure Information:
Title
Performance Characteristics : Clinical Sensitivity (True Positive Rate) and Clinical Specificity (True Negative Rate) in Comparison to the Reference Method
Description
To establish the performance characteristics of the GenePOC CDiff System for its use in determining the presence of CDiff in liquid/unformed stool specimen obtained from patients suspected of having C. difficile infection (CDI).
Sensitivity will be established as the proportion of positives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method.
Specificity will be established as the proportion of negatives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method.
Time Frame
At the time of the results with Reference Method is confirmed, up to 3 months
Secondary Outcome Measure Information:
Title
Positive and Negative Predictive Values (PPV and NPV)
Description
To estimate the Positive and Negative Predictive Values (PPV and NPV) of the GenePOC CDiff System.
PPV is the percentage of true positives out of all positive results (true positive/true positive + false positive).
NPV is the percentage of true negatives out of all negative results (true negative/true negative +false negative.).
Time Frame
At the time of the results with Reference Method is confirmed, up to 3 months
Title
Unresolved Sample Results
Description
To estimate the rate of unresolved results for the GenePOC CDiff System due to Sample Processing control failure (unresolved sample results).
Time Frame
At the time of the results with Reference Method is confirmed, up to 3 months
Title
Indeterminate Sample Results
Description
To estimate the rate of indeterminate results for the GenePOC CDiff Test due to an Instrument failure (indeterminate sample results).
Time Frame
At the time of the results with Reference Method is confirmed, up to 3 months
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Unformed Stool specimens from patients suspected of having CDI for whom diagnostic tests are indicated and ordered;
At least 1.25mL of unformed stool specimen (defined as specimen assuming the shape of its container);
Only one (1) specimen per patient will be included in the study;
Materials use within their expiration date;
Transport, storage times, and conditions (e.g. room temperature and/or refrigerated) within requested indications.
Exclusion Criteria:
Specimens from patients for whom CDI diagnostic tests have not been ordered;
Transport and storage times and conditions that exceed these Study Protocol requirements;
Formed or hard stool specimens or rectal swabs.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Patrice Allibert
Organizational Affiliation
Meridian Bioscience, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Wishard Health Services
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
John Hopkins University School of Medicine
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Facility Name
Detroit Medical Center University Laboratories
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Tricore Laboratory University of New Mexico
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87102
Country
United States
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Mount Sinai Hospital Joseph and Wolf Lebovic Health Complex
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X5
Country
Canada
Facility Name
McGill University Health Centre
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H4A 3J1
Country
Canada
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains
We'll reach out to this number within 24 hrs